Oxidative Processes In Vascular Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
The process that turns cut fruit brown when it is exposed to air is thought to cause disease of our blood vessels and heart as we age. Despite what we first thought, 'blocking' this oxidation process with antioxidant supplements does not lower heart disease. This is because oxidation not only causes harm but also is useful and essential for normal body function. Our research program aims to show which oxidative processes are needed for blood vessel health or cause vessel disease.
Pathophysiology And Treatment Of Malaria In Our Region
Funder
National Health and Medical Research Council
Funding Amount
$951,005.00
Summary
Malaria continues to kill 420,000 people/year. I will lead a team of clinical scientists in identifying how each of the different malaria parasites cause damage to small blood vessels, kidneys and other organs, and will test whether two different drugs can improve these processes and reduce illness. Many of my previous research findings have changed malaria treatment in Australia and across SE Asia, and, where appropriate, I will use new research findings to improve treatments.
Resistant Hypertension: Causes, Consequences, And Novel Therapeutic Approaches
Funder
National Health and Medical Research Council
Funding Amount
$713,517.00
Summary
Two thirds of all strokes and half of all coronary artery disease world-wide can be attributed to uncontrolled blood pressure. Patients with resistant hypertension are at specifically high risk. While the exact reasons remain obscure, work from my group suggests that sympathetic nervous system activation represents a common pathway. Based on these findings the ultimate goal of my research program is to develop novel and more effective treatment strategies for resistant hypertension.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
Improving Outcomes In Heart Failure Through Basic, Clinical And Translational Research
Funder
National Health and Medical Research Council
Funding Amount
$951,005.00
Summary
Heart failure (HF) is a common, chronic cardiovascular condition characterised by a reduced capacity of the heart to function. Patients with HF have a poor quality of life and significantly reduced survival. My proposed programme of research will improve the understanding of heart failure (HF) and lead to better treatments.
Personalised Exercise As Medicine. Optimising The Prescription To Maximise The Benefit
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
Humans have never been less physically active than in contemporary Western society. These studies will provide an evidence-basis to address the inactivity epidemic by laying the foundation for personalised and effective exercise prescriptions, to which people are more likely to adhere.
Sun Exposure, Vitamin D And Photohealth Over The Lifetime
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Australia is a sunny country with a diverse population. Inappropriate sun exposure for skin type leads to skin cancer (mainly in the fair-skinned) and vitamin D deficiency (particularly in the darker-skinned). Potential benefits of sun exposure are broader than vitamin D production, but remain ill-defined. There are few data on appropriate sun exposure for children. This research fellowship builds the evidence to guide sun exposure messages.
I am a matrix biologist determining the molecular mechanisms and novel therapeutic targets for fibrosis (tissue scarring). In particular, my research, which has a strong translational focus, is involved with elucidating the anti-fibrotic potential of the relaxin peptide-hormones (either alone or as an adjunct therapies to existing/other novel treatments) – as a means of developing therapeutic strategies for the treatment of cardiac and renal fibrosis.
This proposal is aimed at improving the health of people with “Disorders of Iron Metabolism”. It focuses on the iron-related diseases hereditary haemochromatosis and colorectal cancer, as well as liver disease, chronic kidney disease and malnutrition. Outcomes from these studies are expected to identify how iron metabolism is impaired, the clinical consequences and new strategies for the prevention and treatment of iron-related diseases.